Victor Grifols : Grifols S.A. President
|
|
The inspiration for the company that Grifols is today had its beginnings in 1910 in Barcelona, Spain, in the pioneering research laboratories of hematologist Dr. J.A. Grifols Roig. Dr. Grifols and his two sons incorporated Laboratorios Grifols in 1940 to advance their work in the developing fields of transfusion, blood banking and clinical analysis.
Today, Grifols is a global corporation that has an unwavering commitment to the development of safer and more effective blood and plasma therapies and processing methods. We take pride in our dedication to service, innovative achievements, a sterling safety record and adherence to the highest standards of honesty and professional ethics.
At Grifols, we benefit from the ability to look at old problems with new eyes, and at the same time, to see new problems with the eyes of experience. As a company dedicated to the health and well-being of others, Grifols believes that experience allied with flexibility and innovation is the key to our future.
- The Grifols group of companies sustains a full and active research and development program that has acquired more than 300 patents in over 30 countries for plasma derivatives alone, and some 200 official product registrations in more than 50 countries. Grifols serves healthcare professionals and patients in over 90 countries around
the world. - Our innovative spirit has led to the formation of our own engineering and design group that has custom designed machines and facilities for both Grifols and other bio-pharmaceutical companies throughout the world.
- Our plasma screening processes were the first approved by the FDA to use NAT testing methods — a process which not only detects a whole virus, but it will also detect non-infectious virus fragments.
- Our FDA approved manufacturing facilities are among the most modern in existence and compares favorably with biological plants anywhere in the world.
|
About Us
